WO2025141542 - PHARMACEUTICAL COMPOSITIONS
National phase entry is expected:
Publication Number
WO/2025/141542
Publication Date
03.07.2025
International Application No.
PCT/IB2024/063322
International Filing Date
30.12.2024
Title **
[English]
PHARMACEUTICAL COMPOSITIONS
[French]
COMPOSITIONS PHARMACEUTIQUES
Applicants **
ABDELWAHAB, Hisham
Inventors
ABDELMONEM, Mohamed
Priority Data
63/615,415
28.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2291 | |
| EPO | Filing, Examination, Granting | 10638 | |
| Japan | Filing, Examination, Granting | 2329 | |
| South Korea | Filing, Examination, Granting | 1866 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,864
Contact Us
Abstract[English]
, wherein the pharmaceutical composition is capable of treating or reducing symptoms of coronavirus disease. Pharmaceutical compositions of the present disclosure can be used for treating or reducing symptoms of COVID-19.[French]
, la composition pharmaceutique pouvant traiter une maladie à coronavirus ou en réduire les symptômes. Les compositions pharmaceutiques de la présente invention peuvent être utilisées pour traiter la COVID-19 ou en atténuer les symptômes.